Cholangiocarcinoma presents a distinct myeloid-derived suppressor cell signature compared to other hepatobiliary cancers

• Published in: bioRxiv
• Main Authors: Bayik, Defne, Lauko, Adam, Roversi, Gustavo A, Serbinowski, Emily, Acevedo-Moreno, Lou-Anne, Lanigan, Christopher, Orujov, Mushfig, Lo, Alice, Tyler, Alban, Silver, Daniel J, Brown, J Mark, Allende, Daniela S, Aucejo, Federico N, Lathia, Justin D
• Format: Paper
• Language: English
• Published: Cold Spring Harbor Cold Spring Harbor Laboratory Press 11.12.2019; Cold Spring Harbor Laboratory
• Edition: 1.2
• Subjects: Antigen-presenting cells; CD11b antigen; Cholangiocarcinoma; Colorectal carcinoma; Genomes; Hepatocellular carcinoma; Histocompatibility antigen HLA; Immunoregulation; Immunotherapy; Liver; Lymphocytes T; Metastases; Metastasis; Neuroendocrine tumors; Pathology; Peripheral blood; Suppressor cells; Tumors; immunosuppression; cholangiocarcinoma; Myeloid-derived suppressor cells; hepatocellular carcinoma
• ISSN: 2692-8205; 2692-8205
• DOI: 10.1101/554600

Myeloid-derived suppressor cells (MDSCs) are immunosuppressive cells that are increased in patients with numerous malignancies including viral-derived hepatocellular carcinoma (HCC). Here, we report an elevation of MDSC in other hepatobiliary malignancies including non-viral HCC, neuroendocrine tumors (NET), colorectal carcinoma with liver metastases (CRLM), but not cholangiocarcinoma (CCA). Investigation of myeloid cell infiltration in HCC, NET and intrahepatic CCA tumors further established that the frequency of antigen-presenting cells was limited compared to benign lesions suggesting that primary and metastatic hepatobiliary cancers have distinct peripheral and tumoral myeloid signatures. Bioinformatics analysis of the Cancer Genome Atlas demonstrated that a high MDSC score in HCC patients predicted poor disease outcome. Mechanistic studies indicated that the oncometabolite D-2-hydroxyglutarate resulting from isocitrate dehydrogenase 1 mutation could be a limiting factor of MDSC accumulation in CCA patients. Given our observation that MDSCs are increased in non-CCA malignant liver cancers, they may comprise suitable targets for effective immunotherapy approaches.